IDEAYA BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT January 31, 2018Investors’ Rights Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
Contract Type FiledApril 26th, 2019 Company Industry JurisdictionThis AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of January 31, 2018, by and among Ideaya Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”).
IDEAYA BIOSCIENCES, INC. 2015 EQUITY INCENTIVE PLAN EARLY EXERCISE STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENTStock Option Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • California
Contract Type FiledApril 26th, 2019 Company Industry JurisdictionAs Escrow Agent for both Ideaya Biosciences, Inc. (the “Company”) and the undersigned purchaser of stock of the Company (the “Participant” ), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Stock Option Grant Notice and Stock Option Agreement (the “Agreement”) between the Company and the undersigned, in accordance with the following instructions:
EVALUATION, OPTION AND LICENSE AGREEMENTEvaluation, Option and License Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • Manchester
Contract Type FiledApril 26th, 2019 Company Industry Jurisdiction
AMENDMENT #1 TO EVALUATION, OPTION AND LICENSE AGREEMENTOption and License Agreement • April 26th, 2019 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations
Contract Type FiledApril 26th, 2019 Company IndustryTHIS AMENDMENT #1 TO EVALUATION, OPTION AND LICENSE AGREEMENT (“Amendment #1”) is made as of April 24th, 2019 (the “Amendment Effective Date”) by and between IDEAYA BIOSCIENCES, INC., a Delaware corporation, having a principal place of business at 7000 Shoreline Court, Suite 350, South San Francisco, California 94080 (“Company”), Cancer Research Technology Limited, a company registered in England & Wales under number 1626049 and located at the Angel Building, 407 St John Street, London EC1V 4AD, England (“CRT”), and The University of Manchester, a public research university located at Oxford Road, Manchester M13 9PL, England (“Manchester”) (with CRT and Manchester, collectively, “Institute”).